EUGLYCEMIC DIABETIC #KETOACIDOSIS WITH #COVID-19 INFECTION IN PATIENTS WITH TYPE 2 DIABETES TAKING #SGLT2 INHIBITORS

Diabetes mellitus is associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Diabetic ketoacidosis (DKA) has also been reported to occur with this virus. A cluster of cases of euglycemic DKA (euDKA) was identified in patients with type 2 diabetes mellitus using sodium-glucose cotransporter-2 inhibitors (SGLT2is) who developed SARS-CoV-2 infection.. ..Five cases of euDKA, presenting with glucose levels <300 mg/dL, were … Continue reading EUGLYCEMIC DIABETIC #KETOACIDOSIS WITH #COVID-19 INFECTION IN PATIENTS WITH TYPE 2 DIABETES TAKING #SGLT2 INHIBITORS

Rate This

A randomized controlled trial of 130 g/day low-#carbohydrate diet in type 2 #diabetes with poor glycemic control

The usefulness of low-carbohydrate diet (LCD) for Japanese patients with type 2 diabetes mellitus (T2DM) has not been fully investigated. Therefore, we compared the effectiveness and safety of LCD with calorie restricted diet (CRD). This prospective, randomized, open-label, comparative study included 66 T2DM patients with HbA1c >7.5% even after receiving repeated education programs on CRD. They were randomly allocated to either the 130g/day LCD group … Continue reading A randomized controlled trial of 130 g/day low-#carbohydrate diet in type 2 #diabetes with poor glycemic control

Rate This

Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Liver disease is highly prevalent among people with type 2 diabetes mellitus (T2DM). We evaluated the dipeptidyl peptidase-4 inhibitor linagliptin in subjects with T2DM and hepatic disorders.. ..Of the 7009 participants (56% white, 39% Asian), 574 had hepatic disorders, most commonly hepatic steatosis (60%). At week 24, adjusted mean ± standard error (SE) change in HbA1c from baseline in those with hepatic disorders was − … Continue reading Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials

Rate This

#Plastics, #EDCs & Health: Authoritative Guide

The Endocrine Society and IPEN (International Pollutants Elimination Network) are proud to present this authoritative and comprehensive report to addresses how plastics can harm human health. An expert overview of twenty years of research shows that plastics pose a threat to public health because they contain a host of hazardous, endocrine-disrupting chemicals (EDCs) that leach and contaminate humans and the environment. The report catalogues EDCs … Continue reading #Plastics, #EDCs & Health: Authoritative Guide

Rate This

Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics and unaware of having NAFLD. At the visit, volunteers were … Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Rate This

#Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial RESEARCH DESIGN AND METHODS The subgroup of 2,605 patients with heart failure and reduced … Continue reading #Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

Rate This

Vitamin #D metabolites and the gut #microbiome in older men

The vitamin D receptor is highly expressed in the gastrointestinal tract where it transacts gene expression. With current limited understanding of the interactions between the gut microbiome and vitamin D, we conduct a cross-sectional analysis of 567 older men quantifying serum vitamin D metabolites using LC-MSMS and defining stool sub-Operational Taxonomic Units from16S ribosomal RNA gene sequencing data. Faith’s Phylogenetic Diversity and non-redundant covariate analyses … Continue reading Vitamin #D metabolites and the gut #microbiome in older men

Rate This

#Older age does not influence the success of #weight loss through the implementation of lifestyle modification

Age is sometimes a barrier for acceptance of patients into a hospital‐based obesity service. Our aim was to explore the effect of age on the ability to lose weight through lifestyle interventions, implemented within a hospital‐based obesity service.. Primary outcome measures were percentage weight loss (%WL) and percentage reduction in body mass index (%rBMI) following implemented lifestyle interventions. Data were stratified according to patient age … Continue reading #Older age does not influence the success of #weight loss through the implementation of lifestyle modification

Rate This

PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against #gestational #diabetes in mice and humans

Pregnancy is a physiological state of continuous adaptation to changing maternal and fetal nutritional needs, including a reduction of maternal insulin sensitivity allowing for appropriately enhanced glucose availability to the fetus. However, excessive insulin resistance in conjunction with insufficient insulin secretion results in gestational diabetes mellitus (GDM), greatly increasing the risk for pregnancy complications and predisposing both mothers and offspring to future metabolic disease. Here, … Continue reading PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against #gestational #diabetes in mice and humans

Rate This

#Levothyroxine dose and risk of atrial #fibrillation: A nested case-control study

Contemporary data on the effect of levothyroxine dose on the occurrence of atrial fibrillation (AF) are lacking, particularly in the older population. Our objective was to determine the effect of cumulative levothyroxine exposure on risk of AF and ischemic stroke in older adults We conducted a population-based observational study using health care databases from Ontario, Canada. We identified adults aged ≥66 years without a history … Continue reading #Levothyroxine dose and risk of atrial #fibrillation: A nested case-control study

Rate This

Effects of oral #semaglutide on energy intake, #food preference, #appetite, control of eating and body #weight in subjects with type 2 #diabetes

Aims To evaluate the effect of oral semaglutide on energy intake and appetite in subjects with type 2 diabetes (T2D). Materials and methods In this randomised, double‐blind, placebo‐controlled, two‐period cross‐over trial, 15 subjects with T2D received 12 weeks’ treatment with once‐daily oral semaglutide (4‐week dose‐escalation from 3 to 7 to 14 mg) followed by placebo, or vice versa. Energy intake was measured during an ad … Continue reading Effects of oral #semaglutide on energy intake, #food preference, #appetite, control of eating and body #weight in subjects with type 2 #diabetes

Rate This

Development of a #hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE

The ability to differentiate patient populations with type 2 diabetes at high risk of severe hypoglycaemia could impact clinical decision making. The aim of this study was to develop a risk score, using patient characteristics, that could differentiate between populations with higher and lower 2‐year risk of severe hypoglycaemia among individuals at increased risk of cardiovascular disease. Two models were developed for the risk score … Continue reading Development of a #hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE

Rate This